Diamond George A, Kaul Sanjay
Division of Cardiology, Cedars-Sinai Medical Center, and the David Geffen School of Medicine, University of California, Los Angeles, California, USA.
J Am Coll Cardiol. 2007 Oct 16;50(16):1604-9. doi: 10.1016/j.jacc.2007.08.010. Epub 2007 Sep 17.
The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial showed that coronary interventional procedures added little to optimal medical therapy with respect to the long-term outcome of patients with stable coronary disease when used as initial therapy. Detractors opine that: 1) the trial was unrealistic in design and the findings were not unexpected; 2) the use of coronary interventional procedures was suboptimal; and 3) the results of COURAGE are not applicable to current clinical practice. We herein reevaluate the evidence with regard to each of these points, and conclude that COURAGE indeed provides relevant new information to assist the practitioner in the appropriate management of patients with stable coronary disease.
COURAGE(利用血运重建和积极药物评估的临床结果)试验表明,对于稳定性冠心病患者,冠状动脉介入手术作为初始治疗手段,在长期预后方面相较于最佳药物治疗并无显著优势。批评者认为:1)该试验设计不切实际,结果在意料之中;2)冠状动脉介入手术的应用并不理想;3)COURAGE试验的结果不适用于当前临床实践。我们在此对这些观点的证据进行重新评估,并得出结论:COURAGE试验确实提供了相关新信息,有助于医生对稳定性冠心病患者进行合理管理。